FindMyKOL

Deborah Armstrong, MD

Enriched profile

Professor of Oncology · Johns Hopkins

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Lutherville, MD · Northeast · United StatesSpecialtyMedical OncologyFocusOvarian / Gynecologic Cancer+9
Active KOLFindMyKOL type: RegionalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding1999–2026Why? →

Deborah Armstrong is Professor of Oncology at Johns Hopkins. ClinicalTrials.gov lists 7 registered studies with this person as an investigator.

Data verified 13 Nov 2026

Overview

Updated 17 Nov 2026

Deborah Armstrong, M.D., is Professor of Oncology at Johns Hopkins. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 5 companies, 4 NIH-funded awards (1999–2026).

  • Top research focus: Ovarian / Gynecologic Cancer
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 5 companies

Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer5 trialsBrenner Tumor1 trialCarcinoma, Endometrioid1 trialCarcinoma, Ovarian Epithelial1 trialCystadenocarcinoma1 trialCystadenocarcinoma, Mucinous1 trialCystadenocarcinoma, Serous1 trialCysts1 trialFallopian Tube Neoplasms1 trialPeritoneal Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Ovarian / Gynecologic CancerBrenner TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialCystadenocarcinomaCystadenocarcinoma, MucinousCystadenocarcinoma, SerousCystsFallopian Tube NeoplasmsPeritoneal Neoplasms

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials—Industry payments4Publications—Enhertugeneric · TrastuzumabClinical trials—Industry payments2Publications—Xgevageneric · DenosumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
AstraZeneca UK LimitedClinical trials—Industry payments13Gynecologic Oncology GroupClinical trials3Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—Amgen Inc.Clinical trials—Industry payments1Daiichi Sankyo Inc.Clinical trials—Industry payments1Facet BiotechClinical trials1Industry payments—GlaxoSmithKline, LLC.Clinical trials—Industry payments1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials ↓
5companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 1999–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record
  • Co-author

    Society of Gynecologic Oncology practice statement on frontline PARPi maintenance therapy in ovarian cancer

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sgo.org ↗

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Nov 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Nov 2026

5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    68%
    Aromatase Inhibitor68%
    Anastrozole100%
    Part D<11 patients
  • Nervous system

    32%
    Benzodiazepine32%
    Lorazepam100%
    Part D<11 patients
Where care is delivered (Part B)22.2% facility · 77.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Nov 2026

4 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 13 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Doximity

    doximity.com/cv/deborah-armstrong-md-f8089f46

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
  • Facebook

    facebook.com/hopkinskimmel/posts/ovariancancer-is-notoriously-difficult-to-detect-says-dr-deborah-armstrong-a-med/1487566533406259

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • Other

    ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/epov-deborah-armstrong

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
  • Other

    care.healthline.com/find-care/provider/dr-deborah-armstrong-1437113255

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →care.healthline.com ↗
  • Other

    ocrahope.org/about/team/scientific-advisory-committee/deborah-armstrong

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ocrahope.org ↗
  • Other

    profiles.hopkinsmedicine.org/provider/deborah-k-armstrong/2706154

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
  • Other

    hopkinsmedicine.org/news/newsroom/news-releases/2020/09/johns-hopkins-hosts-webinar-series-about-gynecologic-cancers-and-survivorship

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
  • Other

    sgo.org/news/practice-statement-on-frontline-parpi-maintenance-therapy-in-ovca-published

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sgo.org ↗
  • Other

    usnews.com/topics/author/deborah-k-armstrong-md

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usnews.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.